Nurix Therapeutics
NRIX
NRIX
119 hedge funds and large institutions have $462M invested in Nurix Therapeutics in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 46 increasing their positions, 34 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
1.01% less ownership
Funds ownership: 91.52% → 90.52% (-1%)
18% less capital invested
Capital invested by funds: $561M → $462M (-$98.8M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Holders
119
Holding in Top 10
–
Calls
$1.75M
Puts
$5K
Top Buyers
| 1 | +$7.71M | |
| 2 | +$6.49M | |
| 3 | +$4.61M | |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$2.34M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.2M |
Top Sellers
| 1 | -$7.49M | |
| 2 | -$6.57M | |
| 3 | -$6.15M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.87M |
| 5 |
Goldman Sachs
New York
|
-$2.23M |